Navigation Links
Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
Date:7/1/2008

DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for hypertension and other potential indications.

Adrenalin is well known as the hormone that triggers the "fight or flight" reaction in response stress or danger. But Addrenex scientists recognized this hormone, and its counterpart in the brain, noradrenalin, as regulators of diverse physiologic functions -- from blood pressure to energy expenditure to thermostatic control.

"No other company is targeting adrenergic regulation as the root cause of conditions," said Moise Khayrallah, CEO of Addrenex. "We built our company to address a wide range of conditions whose symptoms are being partially managed by drugs currently on the market, but whose origins have never been specifically treated."

Last year the company efficiently advanced its first products, Clonicel(R) to treat attention deficit hyperactivity disorder and CloniBID to treat hypertension, into Phase 3 clinical trials. In July 2007, Addrenex licensed both products to Sciele Pharma for $6 million in upfront equity, $11 million in milestones, and future royalty payments on product sales.

One year later, the company has signed this second, larger deal, to include up to $27 million in development and regulatory milestones and future royalty payments on product sales. In addition, Sciele will pay all development costs.

"The partnership with Sciele is particularly rewarding because validates our work to date and confirms that our products may fill a critical gap in the treatment of debilitating conditions," said Khayrallah.

Addrenex began its foray into drug development by tweaking an existing drug, clonidine, to extend its benefits and reduce bothersome side effects. Company co-founder Joseph Ho
'/>"/>

SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
2. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
3. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Raptor Pharmaceuticals Closes $10 Million Private Placement
6. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
7. VIA Pharmaceuticals Set to Join Russell Microcap Index
8. Wyeth Pharmaceuticals Announces Organizational Change
9. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma ... a recommended approach for protecting personal data in ... researchers, patients and others. The document describes an ... information from CSRs and other related clinical trial ... The goal of the TransCelerate CSR Redaction ...
(Date:9/2/2014)... September 02, 2014 Myriant Corporation, ... signage of a distribution agreement with Azelis Group, ... distributing Myriant’s bio-succinic acid in the Nordics, Benelux, ... targeting customers in the industrial and base chemicals ... Azelis offers a far-reaching chemical portfolio with extensive ...
(Date:9/2/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... (PTO) has issued a patent related to NB32, the ... is a fixed-dose combination of naltrexone sustained release (SR) ... claims methods for treating insulin resistance using a composition ... If NB32 is approved for use in ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... presented today show that RAPAFLO(R) (silodosin) significantly reduced ... pain syndrome (CP/CPPS).  In the study presented at ... RAPAFLO(R) also significantly improved urinary symptoms as well ... pelvic pain syndrome (CP/CPPS) is a common condition ...
... 2011 Brian Olson didn,t exactly fit the image of an ... first to admit it. "I had just a GED and was ... math." With a vague notion that he wanted to ... enrolled in basic chemistry and biology courses as a freshman. ...
... May 17, 2011 P f enex ... has submitted a Biologics Master File (BMF) to the United ... carrier protein to support the development of conjugate vaccine products ... supplying cGMP grade CRM197 carrier protein to multiple partners in ...
Cached Biology Technology:Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 2Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 3Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 5Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 6From GED to PhD: Borough of Manhattan Community College's Brian Olson Faces Academic Deficits Only to Be Rewarded with Acceptance to CUNY's PhD Program in Biochemistry 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3
(Date:9/2/2014)... lithographic limestone is well known as a result ... area (for example, Archaeopteryx). Now, for the first ... French equivalent of these outcrops - discoveries which ... water treader. , Despite the abundance of fossils ... been obtained from the Late Kimmeridgian equivalents of ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
(Date:9/1/2014)... U.S. has improved steadily in recent yearsspurred in large ... remains poor and disparities continue to widen among socioeconomic ... Harvard School of Public Health (HSPH). , "The study ... extensive efforts by many groups and individuals to improve ... also indicates that these efforts need to be expanded," ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... has identified a lung protein that appears to play ... an antibody to block its activity, Indiana University scientists ... the protein, a cytokine named EMAPII, could provide a ... M.D., associate professor of medicine at the Indiana University ...
... take to regenerate a limb? Biologists have long thought that ... cells that can generate any tissue in the body. But ... regrow the complete organ, at least in zebrafish. Researchers ... shown that cells capable of regenerating a zebrafish fin do ...
... has worked with wireless sensor network developers Senceive, ... across critical structures in the UK that will ... Senceive,s main application area is long-term infrastructure monitoring. ... used to assess the condition of railway structures, ...
Cached Biology News:Protein could offer target to reduce lung damage from smoking-caused emphysema 2Zebrafish regrow fins using multiple cell types, not identical stem cells 2NPL helps Senceive to offer improved monitoring of structural assets across the UK 2
... Monoclonal Mouse Antibody to Cytokeratin 5 / ... a high molecular weight, basic type of ... the superficial cell layers of stratified epithelia ... and in mesothelial cells and mesothelioma. Cytokeratin ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Biology Products: